Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.38−0.11 (-7.38%)

Close on Nov 13, 2026Market cap $129.33MP/E –Yield –

Innate Pharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Innate Pharma's pe ratio was 113.8× on Feb 28, 2020.

Period	Period end	Value	Change (pts)
2020	Feb 28, 2020	113.8×	−0.9
2019	Dec 31, 2019	114.7×	–

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Revenue growth-55.2% · median -18.4%

Operating margin-599.8% · median -1693.7%

Advertisement
300 × 250

See a number that looks wrong?